证券代码：603368 证券简称：柳药集团 （一）介绍公司 2025 年前三季度经营情况 公司 2025 年前三季度实现营业收入 157.58 亿元，同比下降 1.47%；实现归属于 上市公司股东的净利润 6.46 亿元，同比下降 9.81%。报告期内，公司业绩较去年同 期有所下滑，主要原因系：占公司营业收入较高的医药批发业务受集采和医院药占 比控制等政策影响，医院药品销售规模呈现阶段性下滑，同时集采品种毛利较低， 同类非集采品种销量受到影响，从而导致批发业务销售下滑和毛利额下降，影响公 司营业收入和归母净利润。从公司三大业务板块看，在医药批发端，公司持续优化 产品结构、强化成本费用和回款账期控制，积极推动医院药械耗材 SPD 项目和 AI 技术在供应链端、医疗端的应用，尽管批发板块营收较去年同期有所下滑，但环比 广西柳药集团股份有限公司 投资者交流会议记录 一、会议基本情况 （四）公司参会人员及职务： 副总裁兼财务总监曾祥兴先生、董事会秘书徐扬先生 （五）调研机构名称（排名不分先后）： 嘉实基金、富安达基金、创金合信基金、红土创新基金、天治基金、金信基金、 泰信基金、中银理财、中国人保、上海同犇投资、中信证 ...

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Viewpoint - Guangxi Liuyuan Group Co., Ltd. has initiated a share repurchase program to utilize its own and raised funds for employee stock ownership plans and equity incentives, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [1]. Group 1: Share Repurchase Basic Information - The company approved a share repurchase plan on July 25, 2025, allowing for the repurchase of A-shares through centralized bidding [1]. - The repurchase period is set for up to 12 months from the board's approval date [1]. Group 2: Progress of Share Repurchase - As of October 31, 2025, the company has repurchased 9.7746 million shares, representing 2.46% of the total share capital, an increase of 0.42% from the last announcement [2]. - The highest repurchase price recorded was RMB 19.07 per share, while the lowest was RMB 17.83 per share, with a total expenditure of RMB 179.6784 million (excluding transaction fees) [2]. Group 3: Compliance and Other Matters - The share repurchase activities are in compliance with relevant laws and regulations, as well as the company's repurchase plan [3]. - The company will continue to make repurchase decisions based on market conditions and fulfill its information disclosure obligations in a timely manner [4].

Group 1 - The core point of the article is that Liu Pharmaceutical Group announced a share buyback, with a total of 9.7746 million shares repurchased, representing 2.46% of the company's total share capital as of October 31, 2025 [2]

Group 1 - The core point of the article is that Liu Pharmaceutical Group (603368.SH) has repurchased a total of 9.7746 million shares, representing 2.46% of the company's total share capital as of October 31, 2025 [1] - The repurchase amount has increased by 0.42% compared to the previous announcement [1] - The highest price for the repurchased shares was 19.07 yuan per share, while the lowest price was 17.83 yuan per share, with a total expenditure of 180 million yuan (excluding transaction fees) [1]

Summary of Key Points Core Viewpoint - Liu Pharmaceutical Group (603368.SH) has announced a share buyback program, indicating a commitment to enhancing shareholder value through capital return strategies [1] Group 1: Buyback Details - As of October 31, 2025, the company has repurchased a total of 9.7746 million shares [1] - The repurchased shares account for 2.46% of the company's total share capital, an increase of 0.42% compared to the previous announcement [1] - The highest price paid for the shares was 19.07 yuan per share, while the lowest price was 17.83 yuan per share [1] - The total amount spent on the buyback is 180 million yuan, excluding transaction fees [1]

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-092 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方 式回购股份方案的公告》（公告编号：2025-053）、《关于以集中竞价交易方式回购 股份的回购报告书》（公告编号：2025-056）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内公告截至上 月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 10 月 31 日，公司通过集中竞价交易方式回购股份数量为 977.46 万股，已回购股份占公司目前总股本的比例为 2.46%，较上次回购进展公告披露数 相比增 ...

Group 1 - The core point of the article is that Liu Pharmaceutical Group has announced a share buyback program, with a total of 9.7746 million shares repurchased, representing 2.46% of the company's total share capital [1] - The repurchase amount has increased by 0.42% compared to the previous announcement [1] - The highest and lowest prices for the repurchased shares were 19.07 yuan per share and 17.83 yuan per share, respectively, with a total expenditure of 180 million yuan (excluding transaction fees) [1]

Summary of Key Points Core Viewpoint - Liu Pharmaceutical Group announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1]. Company Actions - As of October 31, 2025, the company has repurchased a total of 9.7746 million shares [1]. - The repurchased shares represent 2.46% of the company's total share capital, an increase of 0.42% compared to the previous announcement [1]. - The highest price paid for the repurchased shares was 19.07 yuan per share, while the lowest was 17.83 yuan per share [1]. - The total amount spent on the buyback is approximately 180 million yuan [1].

Group 1 - The company announced a share repurchase plan from July 25, 2025, to July 24, 2026, with an expected amount of 100 million to 200 million yuan for employee stock ownership plans or equity incentives [1] - As of October 31, 2025, the cumulative repurchased shares amounted to 9.7746 million shares, accounting for 2.46% of the total share capital, an increase of 0.42% from the last report [1] - The highest transaction price was 19.07 yuan per share, while the lowest was 17.83 yuan per share, with a total amount paid of 179.6784 million yuan [1]